A third prize in the i-Lab Competition for another startup created from Virnext. 2023-07-13

AIS Biotech, spun off from our R&D partnership with the Center for Research on Plant Macromolecules CERMAV, is the winner in the Health theme of the 25th edition of the i-Lab competition, organized by the Ministry of Higher Education, Research and Innovation in partnership with bpifrance. AIS Biotech project is to develop a new class of anti-infective biomedicines based on complex biosynthetic glycopolymers, is one of the 79 projects selected from among the 400 applications, which will be supported by the State via France2030.

The i-Lab competition promotes the results of public research through the creation of innovative technology companies and by financing the best research and development projects for the finalization of an innovative technological product, process or service. In 24 years of existence, i-Lab program has become a privileged point of passage for initiators of innovative projects and a quality label unanimously recognized by deeptech investors: 3,707 winners, for €526 million mobilized and 2,224 innovative technology companies created.

This prize once again rewards the committed policy of promoting academic research and technology transfer of our platform, which has already resulted in the creation of biotech as Signia Therapeutics, i-lab2017 winner and Vaxxel, i-lab2019 winner; and innovative service companies as VirHealth and VirexpR.

We would like to thank our partners Lyon Ingénierie Projet, EZUS Lyon, Université Claude Bernard Lyon 1, Région Auvergne-Rhône-Alpes and bpifrance for their long-standing support and their confidence in our R&D work, in our commitment to innovation and in our economic model, as well as our main R&D partners Cynbiose, Epithelix, Université Laval, GIMAP and Ciqle.